PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES

Update Il y a 4 ans
Reference: EUCTR2008-005182-66

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the safety and efficacy of the 10 mg intravenous (IV) dose of tanezumab in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label tanezumab therapy.


Inclusion criteria

  • PAIN DUE TO BONE METASTASES